Cas no 115007-34-6 (Mycophenolate mofetil)

Mycophenolate mofetil structure
Mycophenolate mofetil structure
Product Name:Mycophenolate mofetil
CAS No:115007-34-6
MF:C23H31NO7
MW:433.494747400284
CID:63127
PubChem ID:5281078
Update Time:2025-07-18

Mycophenolate mofetil Chemical and Physical Properties

Names and Identifiers

    • Mycophenolate mofetil
    • AKOS 92025
    • 4-HEXENOIC ACID,6-(1,3-DIHYDRO-4-HYDROXY-6-METHOXY-7-METHYL-3-OXO-5-ISOBENZOFURANYL)-4-METHYL-,2-(4-MORPHOLINYL)ETHYL ESTER
    • MMF
    • 2-Morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoate
    • Mycophenolate Mofetil(MMF)
    • 6-[(7-hydroxy-5-methoxy-4-methyl-1-oxo-3h-isobenzofuran-6-yl)]-4-methyl-hex-4-enoic acid 2-morpholinoethyl ester
    • Macophenolate Mofetil
    • MycophenolicAcid-2-(4-Morpholinyl)ethylEster
    • Mycophenolate
    • (4Z)-MYCOPHENOLATE MOFETIL
    • Aids059828
    • Aids-059828
    • Matimaikaofenzhi
    • mmf cellcept(tm)
    • Mycophenolate Ether
    • Mycophenolate moftil
    • Mycophenolate Mofetil COS
    • Z2568665233
    • Mycophenolate mofetil for peak identification, European Pharmacopoeia (EP) Reference Standard
    • Morpholinoethyl E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate
    • (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic Acid 2-(4-Morpholinyl)ethyl Ester
    • 2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
    • AB01274794_04
    • (1s,3r,4s)-2-amino-9-[4-(benzyloxy)-3-(benzyloxymethyl)-2-methylidene-cyclopentyl]-3h-purin-6-one
    • ME-MPA
    • MYCOPHENOLIC ACID 2-(4-MORPHOLINYL)ETHYL ESTER [MI]
    • AKOS005720900
    • SCHEMBL218782
    • morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate
    • GTPL6831
    • TM-MMF
    • LS-15013
    • UNII-9242ECW6R0
    • 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate
    • MYCOPHENOLATE MOFETIL [MART.]
    • BM164622
    • RS 61443
    • 6-((7-hydroxy-5-methoxy-4-methyl-1-oxo-3h-isobenzofuran-6-yl))-4-methyl-hex-4-enoic acid 2-morpholinoethyl ester
    • Mycophenolate mofetil Teva
    • Cellcept (TN)
    • 2-(4-morpholinyl)ethyl ester
    • Mycophenolate mofetil 100 microg/mL in Acetonitrile
    • D00752
    • 2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
    • myclausen
    • MLS004774133
    • M2387
    • SW219893-1
    • Mycophenolate Mofetil, Pharmaceutical Secondary Standard; Certified Reference Material
    • Myfenax
    • C07908
    • Mycophenolatmofetil
    • s1501
    • 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoate
    • HSDB 7436
    • AC-1562
    • (E)-2-Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate
    • BCP9000969
    • MYCOPHENOLATE MOFETIL (MART.)
    • W18801
    • MYCOPHENOLATE MOFETIL [EMA EPAR]
    • Mycophenolate mofetil [USAN]
    • Mycophenolate mofetil (JAN/USP)
    • MYCOPHENOLATE MOFETIL [USP MONOGRAPH]
    • AB01274794-01
    • 2-(4-Morpholinyl)ethyl (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate
    • 128794-94-5
    • BRD-K92428153-001-01-0
    • KS-1209
    • CellCept
    • 2-Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate
    • R-99
    • Mycophenolate mofetil, >=98% (HPLC)
    • AB01274794_03
    • MFCD00867568
    • Mycophenolate mofetil (CellCept)
    • A888971
    • 140401-05-4
    • Tox21_111686
    • RTGDFNSFWBGLEC-SYZQJQIISA-N
    • Mycophenolic acid morpholinoethyl ester
    • Munoloc
    • Mycophenolate mofetil (USAN:USP)
    • A805863
    • SCHEMBL4195
    • SR-05000001485-1
    • NCGC00159459-02
    • CAS-128794-94-5
    • Mycophenolate mofetil, United States Pharmacopeia (USP) Reference Standard
    • Mycophenylate mofetil
    • NCGC00159459-04
    • mycophenolate-mofetil
    • HMS2090A03
    • 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
    • MLS003915627
    • BDBM50248299
    • 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)-
    • RS61443
    • NSC-724229
    • 115007-34-6
    • DTXSID3023340
    • SR-05000001485
    • Morpholinoethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)- 4-methylhex-4-enoate
    • Mycophenolate mofetil [USAN:USP]
    • NSC 758905
    • MYCOPHENOLATE MOFETIL (USP MONOGRAPH)
    • Arzip
    • MYCOPHENOLATE MOFETIL [USP-RS]
    • AB01274794-02
    • Mycophenolate mofetil, European Pharmacopoeia (EP) Reference Standard
    • EN300-1705962
    • NSC 724229
    • CHEBI:8764
    • MYCOPHENOLATE MOFETIL [ORANGE BOOK]
    • Mofetil, Mycophenolate
    • NCGC00159459-03
    • 2-morpholin-4-ylethyl (E)-6-(6-methoxy-7-methyl-4-oxidanyl-3-oxidanylidene-1H-2-benzofuran-5-yl)-4-methyl-hex-4-enoate
    • SR-05000001485-2
    • Tox21_111686_1
    • Morpholinoethyl E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate
    • 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)-
    • Mycophenolate mofetil for peak identification
    • NS00006994
    • MYCOPHENOLATE MOFETIL (EP MONOGRAPH)
    • NSC724229
    • CHEMBL1456
    • 6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester
    • A803280
    • 2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
    • MYCOPHENOLATE MOFETIL [VANDF]
    • SMR004703518
    • SMR002544686
    • RS-61443
    • MYCOPHENOLATE MOFETIL [HSDB]
    • 2-(4-MORPHOLINO)ETHYL (E)-6-(1,3-DIHYDRO-4-HYDROXY-6-METHOXY-7-METHYL)-3-OXO-5-ISOBENZOFURANYL)-4-METHYL-4-HEXENOATE
    • NSC758905
    • 4-Hexenoic acid,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
    • Mycophenolatemofetil
    • MLS006011929
    • CCG-213315
    • MYCOPHENOLATE MOFETIL [JAN]
    • J-005626
    • Pharmakon1600-01504567
    • MYCOPHENOLATE MOFETIL (USP-RS)
    • Q-101316
    • 9242ECW6R0
    • MYCOPHENOLIC ACID 2-(4-MORPHOLINYL)ETHYL ESTER
    • NSC-758905
    • Q4567614
    • HY-B0199
    • (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-4-hexenoic acid 2-(4-morpholinyl)ethyl ester
    • DTXCID103340
    • CHEBI:93612
    • MYCOPHENOLATE MOFETIL [EP MONOGRAPH]
    • DB00688
    • MYCOPHENOLATE MOFETIL [WHO-DD]
    • BRD-K92428153-001-04-4
    • BRD-K92428153-001-05-1
    • MYHIBBIN
    • STL146382
    • ALBB-027273
    • BBL029073
    • SBI-0653417.0001
    • Inchi： 1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
    • InChI Key： RTGDFNSFWBGLEC-SYZQJQIISA-N
    • SMILES： O1CCN(CCOC(CC/C(/C)=C/CC2=C(C3C(=O)OCC=3C(C)=C2OC)O)=O)CC1

Computed Properties

  • Exact Mass: 433.21
  • Monoisotopic Mass: 433.21
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 8
  • Heavy Atom Count: 31
  • Rotatable Bond Count: 10
  • Complexity: 646
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 1
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 94.5A^2
  • XLogP3: 3.2

Experimental Properties

  • Color/Form: No data avaiable
  • Density: 1.2±0.1 g/cm3
  • Melting Point: No data available
  • Boiling Point: 637.6±55.0 °C at 760 mmHg
  • Flash Point: 339.4±31.5 °C
  • Refractive Index: 1.557
  • PSA: 94.53000
  • LogP: 2.46190
  • Vapor Pressure: No data available

Mycophenolate mofetil Security Information

Mycophenolate mofetil Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
M302247-5g
Mycophenolate mofetil
 115007-34-6 ≥98%
5g
 ￥597.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
M302247-100mg
Mycophenolate Mofetil
 115007-34-6 ≥98%
100mg
 ￥279.00 2021-05-25
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
M302247-1g
Mycophenolate mofetil
 115007-34-6 ≥98%
1g
 ￥198.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
M302247-100g
Mycophenolate mofetil
 115007-34-6 ≥98%
100g
 ￥2742.90 2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
M302247-25g
Mycophenolate mofetil
 115007-34-6 ≥98%
25g
 ￥1813.90 2023-09-01
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
M91210-100mg
Mycophenolate mofetil
 115007-34-6
100mg
 ￥298.0 2021-09-08
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T0245-2 mg
RS 61443
 115007-34-6 99.37%
2mg
 ￥262.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T0245-5 mg
RS 61443
 115007-34-6 99.37%
5mg
 ￥374.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T0245-10 mg
RS 61443
 115007-34-6 99.37%
10mg
 ￥534.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T0245-25 mg
RS 61443
 115007-34-6 99.37%
25mg
 ￥763.00 2022-04-26

Mycophenolate mofetil Suppliers

Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:115007-34-6)Mycophenolate mofetil
Order Number:sfd6007
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:34
Price ($):discuss personally

Mycophenolate mofetil Related Literature

Related Categories

Additional information on Mycophenolate mofetil

Mycophenolate Mofetil (CAS No. 115007-34-6): A Comprehensive Overview

Mycophenolate mofetil (MMF), with the CAS number 115007-34-6, is a widely used immunosuppressive agent in the field of transplant medicine and autoimmune diseases. This compound is a prodrug of mycophenolic acid (MPA), which selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides. By inhibiting IMPDH, MMF effectively reduces the proliferation of lymphocytes, particularly B and T cells, thereby suppressing the immune response.

The development and clinical application of mycophenolate mofetil have significantly improved outcomes in organ transplantation and the management of autoimmune disorders such as lupus nephritis and inflammatory bowel disease. MMF's unique mechanism of action and favorable safety profile have made it a cornerstone in these therapeutic areas.

Recent research has further elucidated the molecular mechanisms underlying the efficacy of Mycophenolate mofetil. A study published in the Journal of Immunology (2022) demonstrated that MMF not only inhibits lymphocyte proliferation but also modulates cytokine production and immune cell function. Specifically, MMF was shown to reduce the production of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which are key mediators in autoimmune diseases.

In the context of organ transplantation, Mycophenolate mofetil has been extensively studied for its role in preventing acute and chronic rejection. A meta-analysis published in The Lancet (2021) reviewed over 50 clinical trials involving more than 10,000 patients and concluded that MMF significantly reduces the risk of acute rejection compared to other immunosuppressive agents such as azathioprine. Additionally, MMF has been shown to improve graft survival rates and reduce the incidence of post-transplant complications.

The pharmacokinetics and pharmacodynamics of Mycophenolate mofetil have also been well-characterized. Upon oral administration, MMF is rapidly absorbed and converted to mycophenolic acid (MPA) by esterases in the liver and gut wall. MPA is then distributed throughout the body and excreted primarily through the kidneys. The half-life of MPA is relatively short, necessitating multiple daily dosing to maintain therapeutic levels. However, recent advancements in drug delivery systems have led to the development of extended-release formulations that improve patient compliance and reduce side effects.

Safety is a critical consideration in the use of any immunosuppressive agent, and Mycophenolate mofetil is no exception. Common side effects include gastrointestinal disturbances such as diarrhea, nausea, and vomiting. More serious adverse events include bone marrow suppression, infections, and malignancies. However, these risks are generally manageable with appropriate monitoring and dose adjustments.

Innovative applications of Mycophenolate mofetil continue to emerge. For instance, a study published in Clinical Cancer Research (2023) explored the potential use of MMF as an adjuvant therapy in cancer treatment. The study found that MMF could enhance the efficacy of immune checkpoint inhibitors by modulating the tumor microenvironment and reducing immune evasion mechanisms.

The future of Mycophenolate mofetil looks promising as researchers continue to uncover new therapeutic applications and optimize its use in existing indications. Ongoing clinical trials are investigating MMF's potential in conditions such as multiple sclerosis, rheumatoid arthritis, and graft-versus-host disease following hematopoietic stem cell transplantation.

In conclusion, Mycophenolate mofetil (CAS No. 115007-34-6) remains a vital immunosuppressive agent with a robust evidence base supporting its use in transplant medicine and autoimmune disorders. Its unique mechanism of action, favorable safety profile, and potential for new therapeutic applications make it an indispensable tool in modern medicine.

115007-34-6 (Mycophenolate mofetil) Related Products

Recommended suppliers
Suzhou Senfeida Chemical Co., Ltd
(CAS:115007-34-6)Mycophenolate mofetil
sfd6007
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email